Literature DB >> 23159063

Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

Ignacio Díaz1, Jose María Pelayo-Terán, Rocío Pérez-Iglesias, Ignacio Mata, Rafael Tabarés-Seisdedos, Paula Suárez-Pinilla, José Luis Vázquez-Barquero, Benedicto Crespo-Facorro.   

Abstract

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remission. The logistic regression analysis revealed that the strongest predictors of achieving clinical remission 1 year away from a first episode of non-affective psychosis were the length of duration of untreated psychosis (DUP), the severity of negative symptomatology and the educational level attained at baseline. The results suggest that: (1) patients with a lengthy DUP, a greater severity of negative symptomatology at baseline and with a lower education level are in a higher risk of not achieving a clinical remission during the first year of treatment; and (2) early intervention clinical programs should aim to reduce the length of DUP in order to provide a better outcome for patients.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159063     DOI: 10.1016/j.psychres.2012.10.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.

Authors:  Ditte L Vernal; Sandeep Kapoor; Aseel Al-Jadiri; Eva M Sheridan; Yehonathan Borenstein; Charles Mormando; Lisa David; Sukhbir Singh; Andrew J Seidman; Maren Carbon; Miriam Gerstenberg; Ema Saito; John M Kane; Hans-Christoph Steinhausen; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-09       Impact factor: 2.576

2.  Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine Learning.

Authors:  Rigas F Soldatos; Micah Cearns; Mette Ø Nielsen; Costas Kollias; Lida-Alkisti Xenaki; Pentagiotissa Stefanatou; Irene Ralli; Stefanos Dimitrakopoulos; Alex Hatzimanolis; Ioannis Kosteletos; Ilias I Vlachos; Mirjana Selakovic; Stefania Foteli; Nikolaos Nianiakas; Leonidas Mantonakis; Theoni F Triantafyllou; Aggeliki Ntigridaki; Vanessa Ermiliou; Marina Voulgaraki; Evaggelia Psarra; Mikkel E Sørensen; Kirsten B Bojesen; Karen Tangmose; Anne M Sigvard; Karen S Ambrosen; Toni Meritt; Warda Syeda; Birte Y Glenthøj; Nikolaos Koutsouleris; Christos Pantelis; Bjørn H Ebdrup; Nikos Stefanis
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

3.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

4.  Speech prosody abnormalities and specific dimensional schizotypy features: are relationships limited to male participants?

Authors:  Jeffrey S Bedwell; Alex S Cohen; Benjamin J Trachik; Andrew E Deptula; Jonathan C Mitchell
Journal:  J Nerv Ment Dis       Date:  2014-10       Impact factor: 2.254

5.  Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population.

Authors:  David C Cicero; Elizabeth A Martin; Theresa M Becker; Anna R Docherty; John G Kerns
Journal:  Psychol Assess       Date:  2014-04-07

Review 6.  The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.

Authors:  Stefan Leucht; Inge Winter-van Rossum; Stephan Heres; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; F Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Shitij Kapur; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2015-03-18       Impact factor: 9.306

Review 7.  Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Authors:  Maren Carbon; Christoph U Correll
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

Review 8.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

9.  A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia.

Authors:  Anmol Singh; Ram Pratap Beniwal; Prachi Kukshal; Triptish Bhatia; B K Thelma; Smita N Deshpande
Journal:  Indian J Psychiatry       Date:  2018 Jan-Mar       Impact factor: 1.759

10.  Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.

Authors:  Paola Bozzatello; Silvio Bellino; Paola Rocca
Journal:  Front Psychiatry       Date:  2019-02-26       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.